The field
Onconephrology
Also written onco-nephrology — and, approached from the oncology side, nephro-oncology. One field, at the intersection of cancer and the kidney.
Onconephrology is the nephrology subspecialty at the bidirectional intersection of cancer and the kidney — the nephrotoxicity of anticancer therapy, AKI and CKD in cancer patients, electrolyte disorders, tumor lysis syndrome, paraneoplastic glomerular disease and drug dosing in renal impairment. The field coalesced around 2010–2014, with the ASN onconephrology forum established in 2011. PMID 25340170 (opens PubMed in a new tab)
This atlas is a citation-grounded reference for the field’s drug-injury half: the nephrotoxicity of chemotherapy, targeted therapy and immunotherapy across 290 anticancer agents, 14 kidney-injury signatures, and 1,625 primary references.
of cancer patients develop AKI within 5 years
Christiansen et al., Eur J Intern Med 2011 · PMID 21767759 (opens PubMed in a new tab)carry hidden kidney impairment at diagnosis
Launay-Vacher et al., Cancer 2007 · PMID 17634949 (opens PubMed in a new tab)higher odds of death with in-hospital AKI
Salahudeen et al., CJASN 2013 · PMID 23243268 (opens PubMed in a new tab)The field, mapped to this atlas
Onconephrology’s classic subtopics, each opening the part of the atlas that covers it.
Nephrotoxicity of chemotherapy & targeted therapy
How anticancer drugs injure the kidney — 290 agents, each with its signature lesion, from cisplatin's tubular necrosis to anti-VEGF thrombotic microangiopathy.
The master atlasThe injury patterns
14 kidney-injury signatures — ATN, AIN, TMA, glomerular disease, electrolyte wasting, crystal nephropathy — each with its culprit drugs and workup.
Injury atlasImmunotherapy and the kidney
Checkpoint-inhibitor nephritis and the wider immune-related adverse-event spectrum, with grade-by-grade management sourced from the society guidelines.
irAE atlasDrug dosing in renal impairment
Which anticancer agents need a renal dose change, at what threshold, and what is dialyzable — the everyday consult question of the field.
Renal dosingTumor lysis syndrome
Massive tumor-cell breakdown flooding the tubule with urate and phosphate — risk stratification, prophylaxis, and the crystal-obstruction mechanism.
TLS deep diveParaproteins & MGRS
Monoclonal gammopathy of renal significance — the lesions a small clone can build, and why 'MGUS' can still be a kidney disease.
MGRS chapterTransplant-associated TMA
The endothelial-injury syndrome after hematopoietic cell transplant — complement and sC5b-9 biomarkers, high-risk features, and the complement-directed toolkit.
TA-TMA pageDoes the kidney recover?
Recovery trajectories, CKD risk and rechallenge dispositions after drug-induced kidney injury, agent by agent.
Renal outcomesThe people building the field
The clinicians and scientists behind the onconephrology literature, recognized by code-tallied bibliometrics.
ContributorsThe literature, as it lands
New onconephrology research from PubMed — nephrotoxicity, immune-related kidney injury, and the field's guidelines — refreshed automatically.
Literature feedEducational reference only — not medical advice. See methods for how the atlas is sourced, and learning paths for a guided way in.